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Abstract
Several studies have highlighted the important role played by murine natural killer (NK) cells in the control of influenza
infection. However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1
influenza virus, are poorly documented. Here, we examined changes in NK cell phenotype and function and plasma cytokine
levels associated with influenza infection and vaccination. We show that absolute numbers of peripheral blood NK cells, and
particularly those of CD56
bright NK cells, decreased upon acute influenza infection while this NK cell subset expanded
following intramuscular influenza vaccination. NK cells exposed to influenza antigens were activated, with higher
proportions of NK cells expressing CD69 in study subjects infected with seasonal influenza strains. Vaccination led to
increased levels of CD25+ NK cells, and notably CD56
bright CD25+ NK cells, whereas decreased amounts of this subset were
present in the peripheral blood of influenza infected individuals, and predominantly in study subjects infected with the
2009 pandemic H1N1 influenza virus. Finally, acute influenza infection was associated with low plasma concentrations of
inflammatory cytokines, including IFN-c, MIP-1b, IL-2 and IL-15, and high levels of the anti-inflammatory cytokines IL-10 and
IL-1ra. Altogether, these data suggest a role for the CD56
bright NK cell subset in the response to influenza, potentially
involving their recruitment to infected tissues and a local production and/or uptake of inflammatory cytokines.
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Introduction
Seasonal influenza epidemics result in an estimated 250,000–
500,000 deaths per year worldwide [1] and in an average of
200,000 hospitalizations [2] and 36,000 deaths per year in the
United States alone [3,4]. Seasonal epidemics are instigated by the
quick spread of influenza virus variants generated by antigenic
drift, a process that facilitates the escape of the virus from the host
immune system from one outbreak to another. As a result,
influenza vaccines need to be reformulated before each annual
epidemic, and while yearly immunization has been the most
efficient way to prevent influenza so far, vaccines do not provide
complete protection [5].
Viral strains included in the vaccine are selected according to
surveillance-based forecasts and contains components of influenza
B, influenza A H1N1 and influenza A H3N2 viruses, which have
accounted for the majority of reported infections for the last three
to four decades. In April 2009, a new strain of influenza A (2009
pandemic H1N1) genetically related to swine influenza viruses but
capable of efficient human-to-human transmission emerged in
Mexico and California and caused the first influenza pandemic
since 1968 [6,7]. While the 2009 pandemic H1N1 virus does not
generally cause a more severe illness than the seasonal strains, it
can trigger acute pulmonary symptoms due to its ability to infect
cells of the lower respiratory tract [8]. Importantly, reassortment
between the seasonal strains and the 2009 H1N1 influenza virus
could lead to the emergence of variants with increased
pathogenicity and/or resistance to current antiviral treatments.
Therefore, it is essential to further understand the mechanisms
underlying the establishment and the maintenance of an effective
immune response during influenza infection.
Recovery from acute influenza infection and resistance to re-
infection rely both on the production of neutralizing antibodies
targeting the hemagglutinin and the neuraminidase glycoproteins,
and on the killing of infected cells by influenza-specific cytotoxic
CD8+ T lymphocytes that mostly target conserved viral proteins
[9,10]. In addition, several studies have highlighted the early and
pivotal role of innate effector cells, and particularly natural killer
(NK) cells, in the control of influenza infection [11–27]. Before the
onset of the adaptive immune response, NK cells are not only
responsible for the production of antiviral cytokines, but they are
also directly involved in the rapid elimination of virally infected
cells. Moreover, besides their direct antiviral activity, NK cells
secrete large quantities of pro- or anti-inflammatory cytokines that
directly modulate the quality of the adaptive immune response,
mainly via their interaction with dendritic cells [28]. NK cells
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population that resides in the healthy lungs and are further
recruited to the respiratory tract within days of influenza infection
[16,25,29,30]. Furthermore, several studies in mice have illustrat-
ed that NK cell depletion leads to augmented morbidity and
mortality from infection [26,27,31] and that impaired activity of
NK cells early in the infection results in a delayed clearance of the
virus from the lungs [21,32]. Finally, in humans, severe and/or
lethal influenza infection with the 2009 pandemic H1N1 virus has
been associated with reduced proportions of NK cells in the
peripheral blood and the lungs [13], yet very little is known about
changes in the phenotype and function of NK cells in acute 2009
H1N1 influenza infection.
Because of their previously recognized implication in the
immune response to influenza, we investigated the phenotype
and function of NK cells as well as the cytokine levels in patients
with acute influenza infection, comparing infection with 2009
circulating strains of human origin and infection with 2009
pandemic H1N1 influenza virus, or in subjects receiving
intramuscular influenza vaccination. We show that acute influenza
infection is associated with a depletion of peripheral blood NK
cells, and particularly CD56
bright NK cells, consistent with their
homing to infected tissues and/or with an increased NK cell
death. Influenza vaccination and infection both lead to NK cell
activation, with the highest levels found in acute influenza with
human viruses. Finally, we describe significant changes in cytokine
concentrations in the plasma of infected subjects, and notably a
marked increase in anti-inflammatory cytokines. These studies
provide insights into innate immune responses following influenza
antigens exposure in humans.
Results
Marked changes in CD56
bright NK cell numbers in acute
influenza infection and following influenza vaccination
Expansion of NK cells has been previously described in various
human acute viral infections and might represent a crucial step to
achieve early effective control of viral replication [33–35].
However, whether infection with seasonal and 2009 pandemic
H1N1 influenza strains differently affect NK cell expansion and
activation has never been investigated. We first examined NK cell
numbers in blood samples from study subjects with acute influenza
caused by either seasonal or 2009 pandemic H1N1 influenza
viruses, or following seasonal intramuscular influenza vaccination.
Absolute numbers of NK cells were decreased in patients infected
with seasonal (p=0.04) and 2009 pandemic H1N1 (p=0.0005)
influenza viruses compared to healthy unvaccinated individuals
(Fig. 1A), whereas percentages of NK cells relative to the total
lymphocyte population were slightly increased in influenza
infected patients, notably in seasonal influenza infection
(p=0.04) (Fig. 1B). Of note, diminished NK cell numbers reflected
a general lymphopenia in the majority of influenza infected
subjects (data not shown).
NK cells are defined as lymphocytes that are CD3-negative and
can be further subdivided according to their expression of CD56
and/or CD16 into three subpopulations with distinct phenotypic
and functional properties, namely CD56
bright (CD3-
CD56+CD162), CD56
dim (CD3-CD56+CD16+) and CD56
neg
(CD3-CD562CD16+) NK cells [36–39]. A drop in the CD56
bright
and CD56
neg subsets of NK cells accounted for most of the
observed decrease in peripheral blood NK cell numbers associated
with seasonal (p=0.0004 and p=0.02) and 2009 pandemic H1N1
(p,0.0001 and p=0.0001) influenza infections (Fig. 1C).
In contrast, in the study subjects receiving influenza vaccines,
both absolute numbers and percentages of NK cells were
significantly higher four days after immunization compared to
one day after injection (p=0.005 and p=0.04, respectively). This
observation could be attributed to an overall increase in all NK
cells subpopulations, namely CD56
bright (p=0.0001), CD56
dim
(p=0.007) and CD56
neg NK cells (p=0.004) after an early drop in
NK cell numbers one day after vaccination, particularly in the
CD56
bright population (p=0.008) (Fig. 1). Altogether, these data
suggest that peripheral blood lymphocytes, including NK cells,
home to infected tissues early in acute infection with both seasonal
and 2009 pandemic H1N1 influenza strains, and that this
recruitment might specifically involve CD56
bright NK cells. On
the other hand, exposure to the inactivated virus through
intramuscular route resulted in an initial drop ultimately leading
to increased amounts of peripheral blood NK cells, which might
be explained by NK cell proliferation and/or recruitment from the
tissues.
Different profiles of peripheral blood NK cell activation in
seasonal or 2009 pandemic H1N1 influenza infection and
influenza vaccination
In order to further determine the NK cell response to influenza,
we assessed the expression of the activation markers CD69 and
CD25 (the a-chain of the IL-2 receptor) on NK cells from patients
infected or vaccinated with influenza. Interestingly, influenza
infection with seasonal strains was associated with significantly
higher proportions and higher absolute numbers of CD69+ NK
cells compared to swine influenza infection (p=0.002 and
p=0.009, respectively) (Fig. 2). Disparities in age, fever and
previous influenza vaccinations could not explain the observed
differences in the NK cell activation status between individuals
infected with 2009 pandemic H1N1 and seasonal influenza strains
(data not shown). When compared to healthy individuals not
exposed to influenza antigens, percentages but not absolute
numbers of NK cells expressing CD69 were higher in acutely
infected subjects (p,0.0001), suggesting that most of the
peripheral blood NK cells that do not home to other tissues
express CD69. CD69 expression also increased on NK cells from
vaccinated individuals, with the highest proportions of activated
NK cells observed one week following injection of the viral
antigens (p=0.004) (Fig. 2A).
Furthermore, infection with the 2009 pandemic H1N1
influenza virus was associated with decreased percentages and
absolute numbers of CD56
bright NK cells expressing CD25
compared to uninfected subjects (p=0.003 and p,0.0001,
respectively) (Fig. 3). An important drop in CD25+ NK cell
counts also occurred in the CD56
bright CD25+ NK cell subset in
patients with seasonal influenza infection (p=0.0004) (Fig. 3C).
Similar to CD56
bright NK cell numbers, influenza vaccination
triggered an initial drop (p=0.05) followed by an increase in
CD56
bright CD25+ NK cells in the blood four days following
administration of the vaccine (p=0.0004) (Fig. 3C). CD25 is
mostly expressed by CD56
bright NK cells, and therefore might
explain why changes in CD25+ NK cells mirror those previously
observed for the CD56
bright NK cell subset.
In accordance with the phenotypic data, peripheral blood NK
cells from patients with seasonal influenza displayed higher levels
of CD107a surface expression in response to MHC-devoid 221
and K562 cell lines compared to NK cells from control subjects
(p=0.001) (Fig. 4). In contrast, NK cells that were exposed to
seasonal influenza virus in vivo tended to have a decreased response
to the human H1N1 influenza virus in vitro (Fig. 4). IFN-c
production following NK cell stimulation with target cells or
Innate Immune Responses to Influenza
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infected subjects (median percentages with ranges after subtracting
background in healthy vs. influenza-infected following stimulation
with H1N1: 0.2 (0–4.3) vs. 0.7 (0.2–1.9); 221 cells: 0.4 (0–5.2) vs.
1.3 (0–2.6); K562 cells: 0.7 (0–9.8) vs. 2.8 (1.1–5.1); data not
shown). CD107a upregulation or IFN-c production in response to
221 or K562 cells did not vary over time in vaccinated individuals
(data not shown).
These results indicate that infection with 2009 pandemic H1N1
influenza virus lead to fewer activated NK cells in the blood of
infected subjects than did infection with seasonal influenza viruses
and that increased numbers of activated NK cells, and notably
CD56
bright NK cells, are found in the peripheral blood between 4
to 7 days after intramuscular vaccination.
Infection with seasonal and 2009 pandemic H1N1
influenza viruses leads to similar changes in cytokine
plasma levels
Decreased amounts of peripheral blood activated CD56
bright
NK cells in acute influenza patients may reflect that the function of
these particular cells is recruited to infected tissues and/or that this
subset of NK cells is subjected to increased cell death rates. As
CD56
bright NK cells have immunoregulatory properties [38], we
examined plasma levels of a panel of cytokines, including those
that can be produced by NK cells, such as IFN-c, MIP-1a and b,
GM-CSF and IL-10, and those that can induce NK cell activation,
proliferation and differentiation, such as IFN-a, IL-2, and IL-15
[40,41]. Plasma concentrations of IFN-c, MIP-1a, MIP-1b and
GM-CSF tended to be lower in patients infected with seasonal and
2009 pandemic H1N1 influenza viruses than in healthy individ-
uals, yet a significant decrease was only observed for MIP-1b in
subjects with pandemic H1N1 influenza infection (p=0.03)
(Fig. 5). In contrast, we found markedly increased levels of
cytokines with anti-inflammatory properties including IL-10
(p=0.005 and 0.002) and IL-1Ra (p=0.01 and p=0.003) in
influenza-infected patients. Regarding cytokines involved in NK
cell activation, plasma levels of IL-2 decreased in infected patients,
notably in seasonal influenza infection (p=0.04), while the
concentration of IL-15 was slightly higher in acute influenza,
and particularly in subjects with 2009 pandemic H1N1 influenza
Figure 1. Changes in NK cell numbers and subset distribution in acute influenza infection and influenza vaccination. Dot plots
represent (A), absolute numbers of NK cells (B), percentages of total NK cells and (C), absolute numbers of CD56
bright (CD3-CD56+CD162), CD56
dim
(CD3-CD56+CD16+) and CD56
neg (CD3-CD562CD16+) NK cells from 17 subjects prior to influenza vaccination, and at day 1 and 4 post-vaccination, 9
patients with acute seasonal influenza and 21 with acute 2009 pandemic H1N1 influenza virus infection. Complete blood counts at baseline were
only available for 13 of the vaccinated subjects. Horizontal lines indicate the median percentages. Differences where p,0.05 are indicated. (N,
healthy subjects prior vaccination; &, healthy subjects post-vaccination; dark grey m, acutely infected with 2009 seasonal influenza strains; light grey
m, acutely infected with 2009 pandemic H1N1 influenza virus). D: day post-vaccination.
doi:10.1371/journal.pone.0025060.g001
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overall three-fold increase in plasma IFN-a2 (not significant).
Importantly, there were no remarkable differences in cytokine
concentrations between patients infected with 2009 pandemic
H1N1 influenza virus and those infected with seasonal influenza
strains. Cytokines concentrations were very low and stable over
time in the plasma of vaccinated subjects (data not shown). In
summary, low levels of cytokines produced by NK cells, among
other cell types, and significantly increased amounts of anti-
inflammatory cytokines were observed in the blood of subjects
with acute influenza infection.
Discussion
In this study, we investigated changes in peripheral blood NK
cell numbers and activation in response to acute influenza
infection, comparing infection with 2009 influenza circulating
strains and 2009 pandemic H1N1 influenza virus. NK cell
phenotype and function following intramuscular immunization
using trivalent inactivated influenza virus vaccines from 2008–
2009 or 2009–2010 were also examined. Influenza infection and
vaccination both affected NK cell counts, the former leading to
decreased and the latter to increased numbers of peripheral NK
cells, with the most significant changes affecting CD56
bright NK
cells expressing the marker of immune activation CD25. Exposure
to influenza antigens was associated with increased percentages of
CD69+ NK cells, notably in the peripheral blood of patients
infected with seasonal strains, consistent with a virus-dependent
state of NK cell immune activation and a more potent cytotoxic
function against target cell lines than NK cells from healthy
subjects. Compared to healthy unvaccinated individuals, acute
influenza infection triggered significant variations in cytokine
concentrations, and a similar cytokine profile was observed in
acutely infected patients independently of the infecting strain.
Reduced numbers of peripheral blood NK cells, and particu-
larly activated CD56
bright NK cells, in patients with acute
influenza infection might reflect homing of these cells to other
tissues, including those of the respiratory tract, as previously
reported in subjects infected with an H1N1 influenza strain [16].
Alternatively, increased apoptosis and activation-induced cell
death might explain the observed decrease in circulating NK
cells. Apoptosis has been proposed to participate in the severe
depletion of peripheral blood lymphocytes associated with other
viral infections [42,43]. In accordance with this hypothesis, lung
inflammatory infiltrates from one subject with fatal H1N1
influenza infection were devoid of NK cells [13]. Moreover, it
Figure 2. Changes in CD69 expression on NK cells in response to influenza infection and vaccination. Dot plots represent (A),
percentages and (B), absolute numbers of CD69+ NK cells from 17 subjects prior to influenza vaccination, and at day 1, 4 and 7 post-vaccination, 9
patients with acute seasonal influenza and 21 with acute 2009 pandemic H1N1 influenza virus infection. Complete blood counts at baseline were
only available for 13 of the vaccinated subjects. (N, healthy subjects prior vaccination; &, healthy subjects post-vaccination; dark grey m, acutely
infected with 2009 seasonal influenza strains; light grey m, acutely infected with 2009 pandemic H1N1 influenza virus). (C) Representative primary
flow panels show percentages of CD69+ CD56
bright, CD56
dim and CD56
neg NK cells prior to and 7 days post-vaccination and in seasonal and pandemic
influenza infection. Percentages of CD69+ total NK cells are indicated.
doi:10.1371/journal.pone.0025060.g002
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thereby triggering NK cell death, and potentially providing a
mechanism for the virus to escape innate immune defenses
[18,44]. Further analysis will be required to evaluate the role
played by trafficking to infected tissues and/or immune cell death
in influenza-associated lymphopenia.
Changes in NK cell counts observed following vaccination
suggest an initial recruitment to the tissues, and potentially at the
site of injection, followed by a substantial release of NK cells, and
notably CD56
bright NK cells, in the blood. NK cell proportions
were not altered in another longitudinal study examining NK cell
responses in individuals immunized against influenza. However,
frequencies of NK cells were first monitored one week after
vaccination, at a time when NK cell numbers also did not
significantly differ compared to baseline in the samples we
analyzed, explaining the discrepancy between our findings, and
suggesting that changes in NK cells following vaccination occur
rapidly [45].
CD56
bright NK cells have a higher capacity to produce cytokines
as well as a more important proliferative potential than other NK
cell subsets [46]. Therefore, NK cell proliferation and production
of inflammatory cytokines rather than cytolytic functions might be
Figure 3. Changes in CD25 expression on NK cells in response to influenza infection and vaccination. (A) Dot plots represent
percentages of CD25+ CD56
bright NK cells from 17 subjects prior to influenza vaccination, and at day 1 and 4 post-vaccination, 9 patients with acute
seasonal influenza and 21 with acute 2009 H1N1 pandemic influenza. (B) Representative primary flow panels show percentages of CD25+ CD56
bright,
CD56
dim and CD56
neg NK cells prior to and at day 1 and 4 post-vaccination as well as in seasonal and pandemic influenza infection. Percentages of
CD25+ total and CD25+ CD56
bright NK cells are indicated in the upper right corner of the total NK cell gate and CD56
bright NK cell gate, respectively.
(C) Dot plots represent absolute numbers of CD25+ CD56
bright NK cells from 17 subjects prior to influenza vaccination, and at day 1 and 4 post-
vaccination, 9 patients with acute seasonal influenza and 21 with acute 2009 pandemic H1N1 influenza virus infection. Complete blood counts at
baseline were only available for 13 of the vaccinated subjects. (N, healthy subjects prior vaccination; &, healthy subjects post-vaccination; dark grey
m, acutely infected with 2009 seasonal influenza strains; light grey m, acutely infected with 2009 pandemic H1N1 influenza virus). Horizontal lines
indicate the median percentages. Differences where p,0.05 are indicated. D: day post-vaccination.
doi:10.1371/journal.pone.0025060.g003
Figure 4. Functional response of NK cells from influenza-
infected subjects. Dot plots represent percentages of CD107a+ NK
cells from 17 healthy subjects prior to influenza vaccination (C) and 7
subjects with acute seasonal influenza infection (Flu) following
incubation with medium alone, H1N1 PR8 influenza virus for 16 h, or
221 and K562 target cells for 4 h at an effector: target ratio of 10:1.
Influenza-stimulation of NK cells was only performed on 10 subjects
prior to vaccination (C).
doi:10.1371/journal.pone.0025060.g004
Innate Immune Responses to Influenza
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control influenza infection. While we are not able to investigate
whether NK cells do proliferate in the respiratory tract of infected
individuals, increased numbers of peripheral blood activated NK
cells, and notably CD56
bright NK cells, four days after vaccination
might indicate expansion and/or recruitment of NK cells from the
tissues to the blood.
In order to further assess NK cell activation in influenza
infection and vaccination, we looked at the expression of CD69
and CD25 at the surface of NK cells and quantified NK cell
function in response to H1N1 or 221 and K562 target cells ex vivo.
Acute influenza infection was associated with increased percent-
ages of CD69+ and decreased absolute numbers of CD25+ NK
cells, suggesting that CD25+ NK cells, and therefore activated
CD56
brightNK cells, might be recruited to the site of infection
and/or might undergo increased apoptosis rates, while CD69 is a
less specific marker of activation that is upregulated on all NK cells
subsets. Increased CD69 expression conferred a higher NK cell-
mediated cytotoxic function against K562 or 221 cell lines yet a
diminished degranulatory activity in response to a secondary
stimulation with H1N1, supporting the hypothesis that NK cells
that can efficiently respond to influenza have been recruited to
infected tissues and are not circulating in the periphery any more.
Alternatively, NK cells might have become anergic to further
restimulation. For instance, exposure to influenza antigens leads to
the downregulation of NKp46, an activating NK cell receptor that
can recognize influenza hemagglutinin, an observation that might
explain the decreased NK cell response to influenza re-stimulation
[47].
Interestingly, percentages of peripheral blood CD69+ NK cells
significantly differ between patients infected with seasonal
influenza strains and subjects with acute swine influenza infection.
While we did not find any correlation with fever, lower
proportions of NK cells expressing CD69 in swine influenza
infection might be associated with generally more serious
symptoms, in accordance with a recent study describing extremely
low numbers of NK cells in cases of severe and/or lethal 2009
pandemic H1N1 influenza infection, and suggesting that NK cell
proportions correlate with the severity of the diseases [13]. Further
investigations, such as gene expression studies, will be required to
identify potential factors accounting for the observed differences in
NK cell activation in seasonal and 2009 pandemic H1N1
influenza virus infections.
Our results support a role for NK cells, and particularly for
CD56
bright NK cells, in the response to influenza. As the
CD56
bright NK cell subset is endowed with immunoregulatory
properties, and the pathogenicity of virulent influenza strains has
been associated with altered innate responses and hypercytokine-
mia [48–50], we quantified the levels of various cytokines in the
plasma of infected and vaccinated subjects. Decreased concentra-
tions of several pro-inflammatory cytokines, including IL-2 and
IFN-c, of the growth factor GM-CSF and of the chemokines MIP-
1a and MIP-1b were observed in infected individuals compared to
healthy subjects, possibly reflecting an uptake of these cytokines by
other immune cells. Alternatively, these cytokines might be
secreted locally in other tissues than blood by cells that have been
recruited to the site of infection. However, it is very likely that
massive local production of cytokines would lead to spillover into
the systemic circulation. Elevated plasma levels of IL-6, IL-12 and
IFN-c in patients with severe influenza were recently reported
[51]. Our study subjects were enrolled through the Massachusetts
General Hospital emergency room and therefore presented
symptoms, yet the fact that they had a moderate rather than a
severe disease might explain the discrepancy between our results
and those published by Heltzer et al. Also, samples from acutely
infected individuals might have been collected too late after
infection to identify IL-12 and IFN-c in the plasma. IL-6 plasma
levels were not examined in our study. Nevertheless, timing issues
could not explain the suppression of cytokines observed in our
influenza-infected subjects. In addition, elevated concentrations of
several pro-inflammatory cytokines have been detected in the
acute symptomatic phase of many viral infections such as severe
acute respiratory syndrome virus, human immunodeficiency virus,
hepatitis C virus and severe influenza virus infections [48,52–54].
Figure 5. Changes in plasma cytokine concentrations associated with acute influenza infection. Columns represent mean concentrations
of indicated cytokines in 7 controls (black), 9 patients with acute seasonal influenza (dark grey) and 21 with acute 2009 pandemic H1N1 influenza
(light grey). For each column, N represents the number of values included in the analysis based on a coefficient of variation ,30. Low out of range
values were set to half of the lowest standard value (1.6 pg/mL). Bars indicate standard error of the mean. * represents p,0.05; ** represents
p,0.001 and *** represents p,0.0001.
doi:10.1371/journal.pone.0025060.g005
Innate Immune Responses to Influenza
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cell death might account for the decreased NK cell production of
cytokines, including IFN-c, GM-CSF, MIP-1a and MIP-1b,
detected in our patients. Surely, further experiments are warranted
to understand the mechanisms underlying the low pro-inflamma-
tory cytokine levels observed in our patients. Nonetheless, in
accordance with previously published studies, we report increased
levels of IFN-a2 in the plasma of influenza-inoculated subjects
[55], yet this cytokine is more likely to derive from plasmacytoid
dendritic cells than from NK cells. Changes in IL-2 and IL-15
levels are consistent with a key role for these cytokines in the NK
cell response to influenza infection as we and others have reported
that IL-2 is required to enhance IFN-c production by NK cells,
while IL-15 promotes NK cell proliferation in response to
influenza (data not shown and [56]).
In contrast, levels of two anti-inflammatory cytokines, IL-1ra
and IL-10, were elevated in influenza infection, probably to limit
damages that could be provoked by an over-activated immune
system. However, the role played by these cytokines in influenza
infection is not clear yet. While IL-1ra treatment has been shown
to increase the survival rate of influenza-infected mice [57], the
impact of IL-10 on the outcome of influenza infection in mouse
models is still controversial [58–60]. Further investigations to
better characterize the role played by these cytokines in seasonal
influenza infection, and notably to identify IL-10- and IL-1ra-
secreting immune cell subsets, are warranted, as other regulatory
responses, such as T cell responses, probably contribute to the
observed immune suppressive profile.
Overall, influenza exposure was associated with changes in
peripheral blood NK cell numbers and activation, consistent with
a role for NK cells in the innate immune response to influenza
antigens. These data contribute to a better understanding of the
innate immune mechanisms at play during acute influenza
infection and vaccination in humans, providing a basis for further
analysis into the contribution of these cells in the control of human
influenza infection.
Materials and Methods
Ethics statement
The study was approved by the Massachusetts General Hospital
Institutional Review Board and each subject gave written
informed consent for participation in the study.
Study subjects
Peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples collected at day 0, 1, 4 and 7 from 17 healthy
volunteers (11 women and 6 men; median age 27 years, range 22–
57 years) immunized intramuscularly with 0.5 ml inactivated
influenza virus vaccines containing 15 ug purified HA from each
of the three seasonal influenza strains. 13 subjects were vaccinated
with FluarixH 2008–2009 formula (GlaxoSmithKline, Dresden,
Germany) containing the following inactivated virus strains: A/
Brisbane/59/2007 IVR-148 (H1N1), A/Uruguay/716/2007
NYMC X-175C (H3N2) and B/Brisbane/3/2007 (influenza B
virus) and 4 subjects received FluzoneH 2009–2010 formula
(Sanofi Pasteur, Lyon, France) which is a mixture of inactivated
A/Brisbane/59/2007 IVR-148 (H1N1), A/Uruguay/716/2007
NYMC X-175C (H3N2) and B/Brisbane/60/2008 (influenza B
virus) influenza viruses. To study NK cell responses to influenza
infection, 30 individuals presenting to the Massachusetts General
Hospital emergency room with acute influenza symptoms were
enrolled in a second cohort (14 women and 16 men; median age
32 years, range 21–62 years). Nine patients (3 women and 6 men;
median age 35 years, range 21–46 years) were enrolled in January
and February 2009 after being positively diagnosed for influenza
with a rapid test and were probably infected with influenza A,
which was the most common strain in circulation at that time. In
addition, 21 patients (11 women and 10 men; median age 32
years, range 21–62 years) clinically diagnosed with pandemic
H1N1 influenza A virus infection between October and December
2009 participated in the study. Blood was drawn only at the time
of enrollment. For both cohorts, a complete blood count and a
white blood cell differential count were performed at each blood
draw.
Analysis of NK cells surface receptors expression and NK
cell function by flow cytometry
PBMCs were isolated by Histopaque density gradient centrifu-
gation (Sigma). To monitor changes in NK cells receptor
expression, thawed PBMCs were stained using CD56-A700,
CD16-APC-Cy7, CD3-Pac Blue and either CD69-PE-Cy7 or
CD25-PE-Cy7 (BD Biosciences). The LIVE/DEADH Fixable Blue
Dead Cell Stain Kit was used prior surface staining to exclude
dead cells. NK cell function was quantified after stimulation of
fresh PBMCs either with major histocompatibility complex class I
(MHC-I)–devoid K562 and 221 cell lines (ATCC) at an effector-
to-target cell ratio of 10:1 as previously described [61] or with the
A/PR/8/34 H1N1 influenza virus (Charles River Laboratories,
Wilmington, Massachusetts, USA). Influenza infection was
performed by adding the virus at an MOI of 5.2 to 10
6 cells
resuspended in 0.1 ml of RPMI-1640 medium without serum.
After one hour of incubation at 37 C with 5% CO2, RPMI-1640
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
100 mg/ml streptomycin and 100 U/ml penicillin was added to a
final volume of 1 ml. 7 mL/ml CD107a-PE-Cy5 antibody (BD
Biosciences) and monensin (GolgiStop; BD Biosciences) at a final
concentrations of 0.9 nM were added immediately to all reaction
tubes and the total stimulation lasted for 4 (cell lines) or 16
(influenza) hours. Unstimulated PBMCs were similarly treated in
parallel to define the background level of degranulation and
PMA/ionomycin (2.5 and 0.5 ug/ml, respectively) served as the
positive control. Fixed cells were analyzed on an LSRII system
using FacsDiva version 8.8.3 (BD Biosciences). The frequency and
phenotypes of NK cells were defined using FlowJo version 7.5.5
(Treestar).
Quantification of plasma cytokines
Plasma concentrations of cytokines in influenza vaccinated and
infected patients were determined using a Milliplex Human
Cytokine Multiplex Immunoassay Kit (Millipore) and read on a
Bio-Plex 200 reader (Bio-Rad Laboratories). Values for which the
coefficient of variation (%CV) was above 30 were excluded
(ranging from 1 to 13 exclusions), resulting in N values analyzed
for each cytokine and each population, as indicated in figure 5.
Low out of range values with a %CV below 30 were set to half of
the lowest standard value (1.6 pg/mL), while low out of range
values that were extrapolated beyond standard range by the
software were set at the value of the lowest standard (3.2 pg/mL).
The kit was customized to detect GM-CSF, IFN-a2, IFN-c, IL-
1ra, IL-1a, IL-1b, IL-2, IL-10, IL-12(p40), IL-12(p70), IL-15, IL-
17, MIP-1a, MIP-1b and TNF-a. Plasma cytokine levels from
subjects prior to vaccination were used as control.
Statistical analyses
Statistical analyses were performed using the GraphPad Prism
software version 5.04. The non-parametric Wilcoxon signed-rank
Innate Immune Responses to Influenza
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25060test was used to assess longitudinal differences in phenotype
frequencies in vaccinated individuals. The non-parametric Mann-
Whitney test was used to compare phenotype frequencies and
cytokine concentrations between influenza-infected patients and
subjects prior vaccination. P-values of ,0.05 were considered
significant.
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